1. Home
  2. AKBA vs FUNC Comparison

AKBA vs FUNC Comparison

Compare AKBA & FUNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

FUNC

First United Corporation

HOLD

Current Price

$44.57

Market Cap

283.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
FUNC
Founded
2007
1900
Country
United States
United States
Employees
N/A
343
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
251.0M
283.6M
IPO Year
2014
2012

Fundamental Metrics

Financial Performance
Metric
AKBA
FUNC
Price
$1.23
$44.57
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$4.67
N/A
AVG Volume (30 Days)
4.1M
26.8K
Earning Date
05-07-2026
04-20-2026
Dividend Yield
N/A
2.80%
EPS Growth
93.94
19.68
EPS
N/A
1.03
Revenue
N/A
$18,426,000.00
Revenue This Year
N/A
$13.05
Revenue Next Year
N/A
$6.56
P/E Ratio
N/A
$42.66
Revenue Growth
N/A
4.01
52 Week Low
$0.82
$31.80
52 Week High
$3.81
$46.30

Technical Indicators

Market Signals
Indicator
AKBA
FUNC
Relative Strength Index (RSI) 46.66 56.06
Support Level $1.16 $41.34
Resistance Level $1.52 $46.27
Average True Range (ATR) 0.07 1.49
MACD -0.02 -0.25
Stochastic Oscillator 7.59 61.16

Price Performance

Historical Comparison
AKBA
FUNC

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About FUNC First United Corporation

First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.

Share on Social Networks: